mitoxantrone hydrochloride liposome + bortezomib + dexamethasone

**Mitoxantrone hydrochloride liposome + bortezomib + dexamethasone** is an investigational three-drug combination regimen primarily studied as a salvage therapy for adults with relapsed or refractory multiple myeloma[1][2][3][4]. - **Mitoxantrone hydrochloride liposome** is a liposome-encapsulated formulation of mitoxantrone, an anthracenedione antineoplastic agent that acts as a cell cycle non-specific anti-tumor drug by intercalating DNA, inhibiting topoisomerase II, and interfering with RNA synthesis[2][4]. - **Bortezomib** is a first-in-class proteasome inhibitor that induces apoptosis in malignant plasma cells by blocking the 26S proteasome, leading to accumulation of damaged proteins and cell death[2]. - **Dexamethasone** is a synthetic glucocorticoid corticosteroid with immunosuppressive and anti-inflammatory properties, widely used as a backbone in myeloma therapy[2]. This combination (often denoted VMitD or MVD regimen) is administered intravenously in cycles, and has shown a high overall response rate (86.7% in phase I trial)[2], with manageable toxicity dominated by hematologic effects (thrombocytopenia, neutropenia, anemia)[2][4]. The liposomal mitoxantrone formulation is designed to enhance tumor targeting and extend drug half-life while reducing toxicity compared to conventional anthracyclines[4]. The regimen is being developed primarily for use in China and is not yet approved for general use outside clinical trials.

Other names

mitoxantrone hydrochloride liposome injection + bortezomib + dexamethasoneLipo-MIT + bortezomib + dexamethasoneMVD regimen